Source:http://linkedlifedata.com/resource/pubmed/id/16757288
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2006-6-7
|
pubmed:abstractText |
The pharmacokinetic interaction between highly active antiretroviral therapy (HAART) and immunosuppressive drugs is a critical element in the management of patients with human immunodeficiency virus infection who undergo orthotopic liver transplantation (OLT). We describe the effect of the coadministration of Amprenavir/Ritonavir (APV/r) and FosAmprenavir (FosAPV) on cyclosporine (CsA) concentrations in two patients receiving OLT for end-stage liver disease due to hepatitis C Virus. Patient 1, who was maintained on 300 mg CsA twice a day with a trough concentration (C(trough)) around 250 ng/mL, restarted HAART 12 days after transplantation with 300 mg APV/r twice a day with corresponding APV C(trough) of 5293 ng/mL and RTV C(trough) of 186 ng/mL. Forty-eight hours after initiation of HAART, C(trough) of CsA was 1200 mg/mL, so it was necessary to reduce the CsA dosage 12-fold (50 mg every day) to achieve a therapeutic effect. In Patient 2, who was maintained on 300 mg CsA twice a day and a corresponding C(trough) of 400 ng/mL, HAART was restarted 12 days post-OLT with FosAPV 1400 mg twice a day. After 48 hours C(trough) of CsA was around 600 ng/mL and C(trough) of FosAPV, 1221 ng/mL. In this case it was necessary to reduce the CsA administration 3.5-fold (175 mg every day). In conclusion, therapeutic drug monitoring was necessary to monitor HAART and CsA post-OLT to prevent toxicity due to both therapies. The use of FosAPV without ritonavir boostering is sufficient to maintain adequate CsA blood concentrations, avoiding any event of toxicity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Carbamates,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphoric Acid Esters,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/amprenavir,
http://linkedlifedata.com/resource/pubmed/chemical/fosamprenavir
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0041-1345
|
pubmed:author |
pubmed-author:BonoraSS,
pubmed-author:CocchiSS,
pubmed-author:CodeluppiMM,
pubmed-author:Di BenedettoFF,
pubmed-author:EspositoRR,
pubmed-author:GennariWW,
pubmed-author:GerundaG EGE,
pubmed-author:GuaraldiGG,
pubmed-author:LuziKK,
pubmed-author:MasettiMM,
pubmed-author:MottaAA,
pubmed-author:PecoraroGG
|
pubmed:issnType |
Print
|
pubmed:volume |
38
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1138-40
|
pubmed:meshHeading |
pubmed-meshheading:16757288-Adult,
pubmed-meshheading:16757288-Anti-HIV Agents,
pubmed-meshheading:16757288-Carbamates,
pubmed-meshheading:16757288-HIV Infections,
pubmed-meshheading:16757288-Hepatitis C,
pubmed-meshheading:16757288-Humans,
pubmed-meshheading:16757288-Immunosuppressive Agents,
pubmed-meshheading:16757288-Liver Transplantation,
pubmed-meshheading:16757288-Male,
pubmed-meshheading:16757288-Metabolic Clearance Rate,
pubmed-meshheading:16757288-Middle Aged,
pubmed-meshheading:16757288-Phosphoric Acid Esters,
pubmed-meshheading:16757288-Sulfonamides,
pubmed-meshheading:16757288-Treatment Outcome
|
pubmed:year |
2006
|
pubmed:articleTitle |
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
|
pubmed:affiliation |
Department of Internal Medicine and Medical Specialties, Infectious Diseases Clinic, University of Modena and Reggio Emilia, Italy. g.guaraldi@unimo.it
|
pubmed:publicationType |
Journal Article,
Case Reports
|